A distinct innate immune signature marks progression from mild to severe COVID-19

Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but immune signatures of mild and severe disease are still not fully understood. Here, we use mass cytometry and targeted proteomics to profile the innate immune response of patients with mild or severe COVID-19 and of healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevrier, Stéphane, Zurbuchen, Yves, Cervia, Carlo, Adamo, Sarah, Raeber, Miro E., de Souza, Natalie, Sivapatham, Sujana, Jacobs, Andrea, Bachli, Esther, Rudiger, Alain, Stüssi-Helbling, Melina, Huber, Lars C., Schaer, Dominik J., Nilsson, Jakob, Boyman, Onur, Bodenmiller, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817872/
https://www.ncbi.nlm.nih.gov/pubmed/33521697
http://dx.doi.org/10.1016/j.xcrm.2020.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817872/
https://www.ncbi.nlm.nih.gov/pubmed/33521697
http://dx.doi.org/10.1016/j.xcrm.2020.100166

Ejemplares similares